Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.34 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.32 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.32 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.32 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.32 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.32 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.31 |
| ▸ | P2RX2 | Q9UBL9 | 5/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18291825 | 0.83 | NOTUM (0.36) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL27812541 | 0.83 | P2RX7 (0.33) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL19962265 | 0.83 | CYP3A4 (0.33) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| Hydrochloric Acid SCHEMBL30615183 | 0.82 | CYP3A4 (0.33) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| Hydrochloric Acid SCHEMBL28480041 | 0.82 | CYP3A4 (0.33) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| Hydrochloric Acid SCHEMBL17823542 | 0.82 | CYP3A4 (0.33) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL24468394 | 0.80 | P2RX3 (0.35) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL31613940 | 0.80 | P2RX3 (0.35) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL10265563 | 0.80 | CHRNA7 (0.36) | CHRNA7 | |
| SCHEMBL3295796 | 0.78 | TRPV4 (0.48) | TSHRTRPV4OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834440-B2 | Beta-lactam derivatives for the treatment of diseases | INSILICO MEDICINE IP LIMITED (HK) | 2023-12-05 | — | — | US | disclosed |
| US-20230364082-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| EP-3784669-B1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMA (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11752149-B2 | Muscarinic acetylcholine M1 receptor antagonists | Pipeline Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230183216-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20230183216-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-06-15 | — | — | US | disclosed |
| US-20230157287-A1 | PESTICIDAL COMPOUNDS | BASF SE (DE) | 2023-05-25 | — | — | US | disclosed |
| US-20160228432-A1 | HETEROARYL PYRIDONE AND AZA-PYRODINE COMPOUNDS | GENENTECH, INC. (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160221945-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-9238655-B2 | Heteroaryl pyridone and aza-pyridone compounds | GENENTECH, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-8921353-B2 | Heteroaryl pyridone and aza-pyridone compounds | GENENTECH, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140378432-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH INC (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140194408-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8716274-B2 | Heteroaryl pyridone and aza-pyridone compounds | GENENTECH, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20130116235-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130071415-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20090203705-A1 | Spiro Compounds As NPY Y5 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221945-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | CYP3A4 1713/4885CYP2D6 881/4885TSHR 3100/4885 |
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | CYP46A1, CYP26A1, CYP4A22 | CYP3A4 26/4885CYP2D6 15/4885TSHR 4693/4885 |
| US-20230364082-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM5 | CYP3A4 1265/4885CYP2D6 1902/4885TSHR 111/4885 |
| US-20160228432-A1 | HETEROARYL PYRIDONE AND AZA-PYRODINE COMPOUNDS | TYK2, BTK, PDXK | CYP3A4 879/4885CYP2D6 1096/4885TSHR 2794/4885 |
| US-20090203705-A1 | Spiro Compounds As NPY Y5 Receptor Antagonists | NPY4R, NPY1R, NPY5R | CYP3A4 1397/4885CYP2D6 2043/4885TSHR 88/4885 |
| US-20230157287-A1 | PESTICIDAL COMPOUNDS | PNMT, CAT, DDT | CYP3A4 628/4885CYP2D6 1185/4885TSHR 2805/4885 |
| US-11752149-B2 | Muscarinic acetylcholine M1 receptor antagonists | CHRM1, CHRM2, CHRM5 | CYP3A4 1265/4885CYP2D6 1902/4885TSHR 111/4885 |
| US-11834440-B2 | Beta-lactam derivatives for the treatment of diseases | QPCT, QPCTL, BCAT1 | CYP3A4 4021/4885CYP2D6 2998/4885TSHR 3851/4885 |
| US-20130071415-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | CYP3A4 2082/4885CYP2D6 1888/4885TSHR 2900/4885 |
| US-20230183216-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | PIR, CYP3A43, CYP1A2 | CYP3A4 19/4885CYP2D6 51/4885TSHR 2222/4885 |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | CYP3A4 932/4885CYP2D6 1055/4885TSHR 2362/4885 |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | CYP3A4 1627/4885CYP2D6 1271/4885TSHR 3747/4885 |
| US-20130116235-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | BTK, PDXK, TYK2 | CYP3A4 743/4885CYP2D6 752/4885TSHR 2642/4885 |
| US-20140378432-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | CYP3A4 932/4885CYP2D6 1055/4885TSHR 2362/4885 |
| US-20140194408-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | BTK, PDXK, TYK2 | CYP3A4 743/4885CYP2D6 752/4885TSHR 2642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.